ALNY Quote, Financials, Valuation and Earnings

BridgeBio Pharma, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of -153.22%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat BridgeBio Pharma, Inc.'s return on equity of --.

Alnylam Pharmaceuticals, Inc. has a consensus price target of $492.17, signalling upside risk potential of 5.77%. On the other hand BridgeBio Pharma, Inc. has an analysts' consensus of $84.65 which suggests that it could grow by 13.23%. Given that BridgeBio Pharma, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe BridgeBio Pharma, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Alnylam Pharmaceuticals, Inc. has a beta of 0.301, which suggesting that the stock is 69.879% less volatile than S&P 500. In comparison BridgeBio Pharma, Inc. has a beta of 1.256, suggesting its more volatile than the S&P 500 by 25.58%.

Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BridgeBio Pharma, Inc. pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are larger than BridgeBio Pharma, Inc. quarterly revenues of $120.7M. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is higher than BridgeBio Pharma, Inc.'s net income of -$184.9M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,934.89x while BridgeBio Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 19.09x versus 40.25x for BridgeBio Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bristol Myers Squibb Co. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of 17.96%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Alnylam Pharmaceuticals, Inc. has a consensus price target of $492.17, signalling upside risk potential of 5.77%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $53.41 which suggests that it could grow by 2.81%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Bristol Myers Squibb Co..

Alnylam Pharmaceuticals, Inc. has a beta of 0.301, which suggesting that the stock is 69.879% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.

Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.77% to investors and pays a quarterly dividend of $0.62 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,934.89x while Bristol Myers Squibb Co.'s PE ratio is 17.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 19.09x versus 2.20x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of 21.32%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Pfizer Inc.'s return on equity of 10.84%.

Alnylam Pharmaceuticals, Inc. has a consensus price target of $492.17, signalling upside risk potential of 5.77%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Pfizer Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Pfizer Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Alnylam Pharmaceuticals, Inc. has a beta of 0.301, which suggesting that the stock is 69.879% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,934.89x while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 19.09x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of 34.76%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Alnylam Pharmaceuticals, Inc. has a consensus price target of $492.17, signalling upside risk potential of 5.77%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $485.36 which suggests that it could grow by 6.12%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Alnylam Pharmaceuticals, Inc. has a beta of 0.301, which suggesting that the stock is 69.879% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,934.89x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 19.09x versus 10.10x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.